Legal & General Group Plc Acquires 20,163 Shares of Immunocore Holdings plc (NASDAQ:IMCR)

Legal & General Group Plc lifted its holdings in Immunocore Holdings plc (NASDAQ:IMCR - Free Report) by 17.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 136,875 shares of the company's stock after buying an additional 20,163 shares during the period. Legal & General Group Plc owned about 0.27% of Immunocore worth $4,038,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in the business. China Universal Asset Management Co. Ltd. increased its stake in Immunocore by 12.9% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,393 shares of the company's stock worth $248,000 after acquiring an additional 960 shares during the last quarter. NEOS Investment Management LLC raised its holdings in Immunocore by 10.9% during the 4th quarter. NEOS Investment Management LLC now owns 11,194 shares of the company's stock valued at $330,000 after buying an additional 1,102 shares during the period. Assetmark Inc. lifted its position in Immunocore by 5.3% in the fourth quarter. Assetmark Inc. now owns 32,171 shares of the company's stock worth $949,000 after buying an additional 1,616 shares during the last quarter. Geode Capital Management LLC boosted its stake in Immunocore by 1.2% during the fourth quarter. Geode Capital Management LLC now owns 35,492 shares of the company's stock worth $1,047,000 after buying an additional 420 shares during the period. Finally, Crossmark Global Holdings Inc. increased its position in Immunocore by 36.7% during the fourth quarter. Crossmark Global Holdings Inc. now owns 38,020 shares of the company's stock valued at $1,121,000 after acquiring an additional 10,217 shares during the last quarter. 84.50% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on IMCR shares. JPMorgan Chase & Co. dropped their price target on shares of Immunocore from $54.00 to $50.00 and set an "overweight" rating for the company in a research note on Monday, April 14th. Morgan Stanley reaffirmed an "equal weight" rating and set a $35.00 target price on shares of Immunocore in a research note on Friday, March 7th. Mizuho decreased their price target on Immunocore from $38.00 to $33.00 and set a "neutral" rating for the company in a research note on Monday, April 7th. HC Wainwright reaffirmed a "buy" rating and issued a $100.00 price objective on shares of Immunocore in a research report on Wednesday, March 12th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $71.00 target price on shares of Immunocore in a research report on Thursday, April 10th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $63.73.

Insider Activity

In related news, Director Bros. Advisors Lp Baker acquired 807,338 shares of the firm's stock in a transaction that occurred on Monday, March 17th. The stock was purchased at an average cost of $29.72 per share, for a total transaction of $23,994,085.36. Following the purchase, the director now directly owns 2,144,060 shares of the company's stock, valued at $63,721,463.20. This trade represents a 60.40 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders own 10.40% of the company's stock.

Immunocore Stock Up 0.4 %

Shares of Immunocore stock opened at $29.52 on Wednesday. Immunocore Holdings plc has a 1 year low of $23.15 and a 1 year high of $62.74. The company has a debt-to-equity ratio of 1.03, a current ratio of 3.78 and a quick ratio of 3.76. The stock has a market cap of $1.48 billion, a price-to-earnings ratio of -31.07 and a beta of 0.75. The firm's 50-day moving average is $28.74 and its two-hundred day moving average is $30.36.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.

Want to see what other hedge funds are holding IMCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Immunocore Holdings plc (NASDAQ:IMCR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.